Wells Fargo’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
ACA
DCM
JT
Wells Fargo's DFTX Position: Q2 2026 in Review
Wells Fargo increased its Definium Therapeutics (DFTX) stake by 205% in Q2 2026, buying an estimated $2.03M and bringing the position to 122,033 shares worth $5.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2712.
Wells Fargo first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.
- Wells Fargo held 122,033 shares of Definium Therapeutics worth $5.74M as of Q2 2026.
- Wells Fargo bought 82,060 Definium Therapeutics shares in Q2 2026, an estimated $2.03M.
- Definium Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2712 holding.
- Wells Fargo first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
- 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.